Welcome to our dedicated page for Harvard Apparatus Regenerative Technology SEC filings (Ticker: HRGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Pipeline breakthroughs in bioengineered tracheas and organ scaffolds make Harvard Apparatus Regenerative Technology’s SEC disclosures dense with clinical data, FDA timelines, and financing details that few investors have time to decode. If you have ever searched, “What does Harvard Apparatus Regenerative Technology report in their SEC filings?” or needed “Harvard Apparatus Regenerative Technology insider trading Form 4 transactions,” you are in the right place.
Stock Titan’s AI reads every new filing the instant it posts to EDGAR, then translates the science and accounting into clear language. Want the “Harvard Apparatus Regenerative Technology’s quarterly earnings report 10-Q filing” without parsing footnotes? Our summaries flag burn-rate changes, trial costs, and liquidity updates in seconds. Need “Harvard Apparatus Regenerative Technology insider trading filings”? Real-time alerts on Form 4 executive stock transactions appear here before most terminals refresh.
- Compare R&D expense trends quarter-over-quarter to gauge runway.
- Monitor “Harvard Apparatus Regenerative Technology Form 4 insider transactions real-time” to spot strategic buying or selling.
- Dive into “Harvard Apparatus Regenerative Technology 8-K material events explained” for fast context on trial approvals, partnership deals, or clinical holds.
Beyond the staples—annual report 10-K simplified, proxy statement executive compensation, and earnings report filing analysis—our platform surfaces patent activity, collaboration agreements, and manufacturing scale-up plans unique to a regenerative-medicine pioneer. Understanding Harvard Apparatus Regenerative Technology SEC documents with AI means fewer hours spent on biotech jargon and more time making informed decisions.
He Junli, who serves as Chief Executive Officer and a director of Harvard Apparatus Regenerative Technology, Inc. (HRGN), purchased 11,225 shares of HRGN common stock in transactions executed between September 2, 2025 and September 22, 2025 at a weighted average price of $1.85 per share. Following these purchases the reporting person beneficially owned 277,275 shares. The Form 4 was signed by a power of attorney on September 24, 2025. The filing discloses no derivative transactions and notes the weighted average price reflects multiple trades; the reporting person will supply transaction-level price details on request.
FAQ
What is the current stock price of Harvard Apparatus Regenerative Technology (HRGN)?
What is the market cap of Harvard Apparatus Regenerative Technology (HRGN)?
